Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002452 · ClinicalTrials.gov registry record · Phase 2
A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002452 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 30 participants.
The verdict
NCT00002452, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with indinavir and if it works well at lowering the level of HIV in the blood (viral load).
Interventions
- DRUG Indinavir sulfate
- DRUG L-756423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002452
The ClinicalTrials.gov registry entry for NCT00002452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002452 about?
NCT00002452 is a clinical study titled "A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir". The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with indinavir and if it works well at lowering the level of HIV in the blood (viral load).
What is the current status of trial NCT00002452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00002452?
The interventions under investigation include: Indinavir sulfate (DRUG), L-756423 (DRUG).
Who is sponsoring clinical trial NCT00002452?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.